Trial Profile
CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use
- 09 Jan 2024 According to ClinicalTrials.gov record the number of arms in the trial has been increased to 2
- 09 Jan 2024 Planned End Date changed from 18 Dec 2023 to 18 Jun 2024.
- 04 Apr 2023 Planned End Date changed from 18 Mar 2023 to 18 Dec 2023.